Cash-Pay GLP-1 Medicines Now Ship Nationwide
Eligible adults with obesity can buy Zepbound or Foundayo at Lilly's self-pay price through LifeMD's virtual care platform.
Updated on Nov. 5, 2026 in Diabetes
Live Poll
Would you consider buying weight-loss medication directly through a cash-pay program?
LifeMD, a Nasdaq-listed virtual primary care provider, announced on November 5, 2026 an arrangement with Eli Lilly that lets its affiliated pharmacy dispense and ship Lilly's self-pay GLP-1 medicines across the United States. Eligible patients prescribed Zepbound or Foundayo through LifeMD can buy them at Lilly's established self-pay price.
Why it matters
For people managing obesity who pay out of pocket or whose insurance does not cover these branded GLP-1 therapies, the arrangement adds a nationwide, cash-pay route to obtaining them. LifeMD says the move strengthens its vertically integrated care platform, which combines clinical evaluation with fulfillment.
This is a commercial announcement of a distribution arrangement rather than a study, so no clinical efficacy or safety results are reported. The source supplies no sample size, trial design, or measured outcomes for Zepbound or Foundayo in this context.
The players
LifeMD
A Nasdaq-listed provider of virtual primary care whose affiliated pharmacy will dispense the medicines.
Eli Lilly and Company
The drugmaker behind Zepbound (tirzepatide) and Foundayo (orforglipron), two GLP-1 medicines used in obesity care.
The details
Eligible patients are first prescribed a Lilly medication by a LifeMD-affiliated healthcare provider after an independent clinical evaluation, then access the program through LifeMD's virtual care platform. LifeMD's licensed mail-order pharmacy fills and ships the prescription. Medications in the program are offered on a cash-pay basis and are not billed to insurance.
Timeline
November 5, 2026: LifeMD announced the arrangement with Eli Lilly and Company.
Health Landscape
Cash-pay access to branded GLP-1 medicines through direct-to-consumer channels has grown as obesity treatments have become a major focus of prescribing. This arrangement adds a virtual-care and mail-order route to that growing self-pay market.
If you have obesity or a related condition and have been paying for GLP-1 medicines out of pocket, this program is one more cash-pay option to ask your clinician about. Whether a GLP-1 medicine fits your situation is worth discussing with your doctor, who can weigh its benefits, side effects, and cost.
The takeaway
Self-pay routes are expanding, but cost and suitability still depend on your individual health picture. Raise the option of a GLP-1 medicine and its out-of-pocket price with your physician before deciding.
Further reading
For broader background on these medicines, explore our Diabetes coverage.
Live Poll
Would you consider buying weight-loss medication directly through a cash-pay program?
